USPTO serial 99007123
OUTPACE
Reviewed by CopyMark Law Group
Status 730Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- THINGVOLD, CALDER J
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with OUTPACE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $349*
Plus Government fees of $150
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Seattle, WA, US
Seattle, WA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Sydney R. Jensen
411 Borel Avenue, Suite 603San Mateo, CA 94402United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Therapeutics for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; cell therapies, in the nature of modified cells, engineered cells, therapeutic agents, and their delivery agents, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; biopharmaceuticals for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; medicines for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; medical preparations for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical products for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; therapeutic pharmaceuticals for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; therapeutic agents for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; biologics in the nature of cells for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; biologics in the nature of viral vectors for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; biologic preparations for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; cells for medical or clinical purposes; viral or non-viral delivery vectors, namely, delivery agents for treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; therapeutic proteins for medical or clinical purposes; antibodies and libraries of antibodies for medical purposes; pharmaceutical preparations for cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorder, and genetic disorders; pharmaceutical preparations for targeted cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical products for cellular therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; gene therapy products, namely, genetically engineered cells, cell components, molecules, proteins and protein complexes; therapeutic preparations, namely, therapeutic antigens for medical purposes and antibodies for medical purposes; engineered cells for medical use; bioengineered cells for medical use; biological preparations for use in cell engineering platforms cultures for medical purposes; biological preparations for use in protein design platforms for medical purposes; biological preparations designed by computational protein platforms for medical purposes; biological preparations designed by AI-powered protein design platforms for medical purposes; pharmaceutical preparations developed with a computational protein design platform for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations developed with AI-powered protein design platforms for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders; pharmaceutical preparations for medical or clinical purposes, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations comprised of cells, cell components, molecules, and viruses for medical or clinical purposes, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations comprised of gene delivery vectors for medical or clinical purposes, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations comprised of proteins for medical or clinical purposes, in particular for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 23, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 23, 2026 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Oct 22, 2026 | EXT1 | SOU EXTENSION 1 FILED | — |
| Oct 22, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 14, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 19, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 19, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 13, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 22, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 5, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 5, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 5, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 5, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 7, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 6, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 6, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 6, 2025 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Oct 6, 2025 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Jul 7, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 7, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 7, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 27, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 17, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 17, 2025 | NWAP | NEW APPLICATION ENTERED | — |